Publications | ALS Therapy Development Institute

Publications By ALS TDI

This section displays a selected list of publications in peer-reviewed journals by researchers at the ALS Therapy Development Institute. Availability of articles may vary depending on the publication source. For more information about any of these publications, please contact us at info@als.net.

Meet Our Scientists Schedule a Lab Tour

Learn About Our ALS Research

Selected Publications in Peer-Reviewed Journals

Straczkiewicz M., Burke K.M., Calcagno N., Premasiri A., Vieira F.G., Onnela J., Berry J.D. Free‑living monitoring of ALS progression in upper limbs using wearable accelerometers. Journal of NeuroEngineering and Rehabilitation (2024).
Anwar I.J., Berman D.M., DeLaura I., Gao Q., Willman M.A., Miller A., Gill A., Gill C., Perrin S., Ricordi C., Ruiz P., Song M., Ladowski J.M., Kirk A.D., Kenyon N.S. The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. Sci Transl Med. (2023).
Gupta, A.S., Patel, S., Premasiri, A., Vieira, F. At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis. Nat Commun 14, 5080 (2023).
Dane, T.L., Gill, A.L., Vieira, F.G., Denton, K.R. Reduced C9orf72 expression exacerbates polyGR toxicity in patient iPSC-derived motor neurons and a Type I protein arginine methyltransferase inhibitor reduces that toxicity. Front. Cell. Neurosci. 17 (2023).
Vieira, F.G., Venugopalan, S., Premasiri, A.S. et al. A machine-learning based objective measure for ALS disease severity. npj Digit. Med. 5, 45 (2022).
Gill, A.L., Premasiri, A.S., Vieira, F.G. Hypothesis and Theory: Roles of Arginine Methylation in C9orf72-Mediated ALS and FTD. Frontiers in Cellular Neuroscience (2021)
Gill, A.L., Premasiri, A.S., Vieira, F.G. Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity Frontiers in Pharmacology (2020)
Gill, A.L., Wang, M.Z., Levine, B., Premasiri, A., Vieira, F.G. Primary Neurons and Differentiated NSC-34 Cells Are More Susceptible to Arginine-Rich ALS Dipeptide Repeat Protein-Associated Toxicity than Non-Differentiated NSC-34 and CHO Cells International Journal of Molecular Sciences (2019)
Gill, C., Phelan, J.P., Hatzipetros, T., Kidd, J.D., Tassinari, V.R., Levine, B., Wang, M.Z., Moreno, A., Thompson, K., Maier, M., Grimm, J., Gill, A., Vieira, F.G. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Scientific Reports (2019)
Tassinari, V. R. and Vieira, F. G. A High-throughput qPCR-based Method to Genotype the SOD1G93A Mouse Model for Relative Copy Number. Bio-protocol. 2019 9(12): e3276. DOI: 10.21769/BioProtoc.3276.
Maier, M., Welt, T., Wirth, F., Montrasia, F., Preisig, D., McAfoose, J., Vieira, F.G., Kulic, L., Spani, C., Strehle, T., Perrin, S., Weber, M., Hock, C., Nitsch, R.M., Grimm, J. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Science Translational Medicine (2018)
Vaughan S.K., Sutherland, N.M., Zhang, S., Hatzipetros, T., Vieira, F., Valdez, G. The ALS-inducing factos, TDP43-A315T and SOD1-G93A, directly affect and sensitize sensory neurons to stress. Scientific Reports (2018)
Vieira, F.G., Hatzipetros, T., Thompson, K., Moreno, A.J., Kidd, J.D., Tassinari, V.R., Levine, B., Perrin, S., Gill, A. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Reports (2017). doi: 10.1016/j.ibror.2017.03.001.
Berry, J.D., Paganoni, S., Atassi, N., Macklin, E.A., Goyal, N., Rivner, M., Simpson, E., Appel, S., Grasso, D.L., Mejia, N.I., Mateen, F., Gill, A., Vieira, F.G., Tassinari, V.R., Perrin, S. Phase IIA Trial of Fingolimod for ALS Demonstrates Acceptable Acute Safety and Tolerability. Muscle & Nerve (2017)
Hatzipetros, T., Kidd, J.D., Moreno, A., Thompson, K., Gill, A., Vieira, F.G. A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. JOVE. in-press. 2015
Vaughan S.K., Kemp, Z., Hatzipetros, T., Vieira, F.G., Valdez, G. Degeneration of proprioceptive sensory nerve endings in mice harboring amyotrophic lateral sclerosis-causing mutations. Journal of Comparative Neurology (2015)
Vieira, F.G., Ping, Q. , Moreno, A., Kidd, J.D., Thompson, K., Jiang, B., Lincecum, J.M., Wang, M.Z., De Zutter, G.S., Tassinari, V.R., Levine, B., Hatzipetros, T., Gill, A., Perrin, S. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. PlosOne (2015)
Perrin, S. Preclinical research: Make mouse studies work. Nature. 2014 Mar 27;507(7493):423-5.
Vieira, F.G *, Ladow, E.*, Moreno, A., Kidd, J.D., Levine, B., Thompson, K., Gill, A., Finkbeiner, S., Perrin, S.Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PlosOne 2014 doi: 10.1371/journal.pone.0091608. eCollection 2014. (*these authors contributed equally to this work)
Hatzipetros, T., Bogdanik, L.P., Tassinari, V.R., Kidd, J.D., Moreno, A., Davis, C., Osborne, M., Austin, A., Vieira, F.G, Lutz, C., Perrin, S. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2013, ISSN 0006-8993 doi: 10.1016/j.brainres.2013.10.013. Epub 2013 Oct 18.
Liu, D., Liu, C., Li, J., Azadoi, K., Yang, Y., Fei, Z., Dou, K., Kowall, N.W., Choi, H.P., Vieira, F.G, Yang, J.H. Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord. PlosOne, 2013, 8(12): e80779. doi: 10.1371/journal.pone.0080779
Boxer, A.L., Gold, M., Huey, E., Hu, W.T., Rosen, H., Kramer, J., Gao, F.B., Burton, E.A., Chow, T., Kao, A., Leavitt, B.R., Lamb, B., Grether, M., Knopman, D., Cairns, N.J., Mackenzie, I.R., Mitic, L., Roberson, E.D., Van Kammen, D., Cantillon, M., Zahs, K., Jackson, G., Salloway, S., Morris, J., Tong, G., Feldman, H., Fillit, H., Dickinson, S., Khachaturian, Z.S., Sutherland, M., Abushakra, S., Lewcock, J., Farese, R., Kenet, R.O., Laferla, F., Perrin, S., Whitaker, S., Honig, L., Mesulam, M.M., Boeve, B., Grossman, M., Miller, B.L., Cummings, J.L. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013 Mar;9(2):189-98. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 10.
Landis, S.C., Amara, S.G., Asadullah, K., Austin, C.P., Blumenstein, R., Bradley, E.W., Crystal, R.G., Darnell, R.B., Ferrante, R.J., Fillit, H., Finkelstein, R., Fisher, M., Gendelman, H.E., Golub, R.M., Goudreau, J.L., Gross, R.A., Gubitz, A.K., Hesterlee, S.E., Howells, D.W., Huguenard, J., Kelner, K., Koroshetz, W., Krainc, D., Lazic, S.E., Levine, M.S., Macleod, M.R., McCall, J.M., Moxley, R.T. 3rd., Narasimhan, K., Noble, L.J., Perrin, S., Porter, J.D., Steward, O., Unger, E., Utz, U., Silberberg, S.D. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012 Oct 11;490(7419):187-91. doi: 10.1038/nature11556.
Lincecum, J.M.*, Vieira, F.G *, Wang, M.Z., Thompson, K., De Zutter, G.S., Kidd, J.D., Moreno, A., Sanchez, R., Carrion, I.J., Levine, B.A., Al-Nakhala, B.M., Sullivan, S.M., Gill, A., Perrin, S. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet. 2010 May;42(5):392-9. doi: 10.1038/ng.557. Epub 2010 Mar 28. (*these authors contributed equally to this work)
Ludolph, A.C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J.P., Mead, R., Niessen, H.G., Petri, S., Pradat, P.F., Robberecht, W., Ruegg, M., Schwalenstöcker, B., Stiller, D., van den Berg, L., Vieira, F.G., von Horsten, S. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11(1-2):38-45. doi: 10.3109/17482960903545334.
Gill, A., Kidd, J.D., Vieira, F.G., Thompson, K., Perrin, S. >No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard model of familial ALS. PlosOne. 2009 Aug 3;4(8):e6489. doi: 10.1371/journal.pone.0006489.
Scott, S., Kranz, J.E., Cole, J., Lincecum, J.M., Thompson, K., Nancy Kelly, Bostrom, A., Theodoss, J., Al-Nakhala, B.M., Vieira, F.G., Ramasubbu, J., Heywood, J.A. Design, power and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9(1):4-15. doi: 10.1080/17482960701856300
Clark, J.C., Brennan, A., Ramesh, T.M., Heywood, J.A. Novel trends in orphan market drug discovery: amyotrophic lateral sclerosis as a case study. Front Biosci. 2002 Aug 1;7:c83-96.
Janson, C.G., Ramesh, T.M., During, M.J., Leone, P., Heywood, J.A. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J. Hematother Stem Cell Res. 2001 Dec;10(6);913-5.

What Do I

Do Next?